Zetonna (Sunovion) launched in US for Allergic Rhinitis

Sunovion Pharmaceuticals Inc. announced the nationwide US availability of Zetonna (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. Zetonna is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older. It is the only dry nasal aerosol approved by the FDA with once daily, one spray per nostril (37 mcg) dosing. Zetonna joins Omnaris (ciclesonide) Nasal Spray as the newest addition in Sunovion's ciclesonide franchise. These treatments offer different experiences for patients, as Omnaris is an aqueous, once-daily, two spray per nostril option for SAR patients 6 and older and PAR patients 12 and older Sunovion thus provides patients with the option of a dry aerosol or aqueous treatment.